Clinical trial Recruiting at 1 site Observational Ages 18 and up

Investigating Biomarkers in Acute Respiratory Distress Syndrome

Official title: The ASSESSMENT of SERPINB3 EXPRESSION, PAR2 and SCCA-PD POLYMORPHISM in PATIENTS with ACUTE RESPIRATORY DISTRESS SYNDROME

Run by University of Padova · NCT06774534 · Data updated 2026-11-12

This study is trying to see if certain markers in the blood can help us understand how Acute Respiratory Distress Syndrome affects the lungs and how severe the condition is in patients.

More Respiratory Failure trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment40 (estimated)
SponsorUniversity of Padova
Academic / other
Locations1 site (Padova, PD)
StatusRecruiting
StartedFebruary 28, 2025
Main results expectedDecember 31, 2028
Study endsDecember 31, 2030
Registry record updatedMarch 5, 2025
Trial IDNCT06774534 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are adults diagnosed with ARDS who require invasive mechanical ventilation.

Probably not a fit

Patients under 18 years, pregnant individuals, or those with chronic inflammatory skin conditions or chronic lung diseases may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on patients diagnosed with Acute Respiratory Distress Syndrome (ARDS) and aims to explore the expression of SERPINB3 and the polymorphism SCCA-PD, as well as the role of protease-activated receptor 2 (PAR2) in the disease's pathophysiology. By conducting a detailed clinical and biomolecular phenotyping, the study seeks to uncover new insights into the mechanisms of lung injury associated with ARDS. The research will analyze how these biomarkers correlate with the severity of lung injury and inflammation in affected patients.

Why it matters

Potential benefit: If successful, this study could lead to personalized treatment strategies for ARDS patients based on their specific biomolecular profiles.

How similar studies have gone: While the specific approach of studying SERPINB3 and PAR2 in ARDS is novel, similar studies have shown promise in understanding biomarkers in other respiratory conditions.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* ARDS DIAGNOSIS
* IMV

Exclusion Criteria:

* Age under 18 years
* Pregnancy status
* Lack of consent to participate in the study
* Contraindications to fiberoptic bronchoscopy and/or BAL (bronchoalveolar lavage)
* Patients with chronic inflammatory skin conditions
* Patients with chronic lung diseases
* Patients with inflammatory respiratory diseases
* Patients with neoplasms such as: squamous cell carcinoma of the cervix, squamous cell carcinoma of the esophagus, lung adenocarcinoma, breast adenocarcinoma, pancreatic adenocarcinoma, hepatocellular carcinoma
* History of active or passive smoking

Where it's running

  • Azienda Ospedaliera di Padova
    Padova, Pd, Italy
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.